miR-410-3p suppresses breast cancer progression by targeting Snail

Ya-Feng Zhang1, Yue Yu1, Wang-Zhao Song2

  • 1The First Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin 300060, P.R. China.

Oncology Reports
|May 26, 2016
PubMed

Insights

MicroRNA-410-3p (miR-410-3p) is downregulated in breast cancer, acting as a tumor suppressor by inhibiting cell proliferation and epithelial-mesenchymal transition through targeting Snail. This finding offers new insights into breast cancer progression.

Area of Science:

  • Molecular Biology
  • Oncology
  • Genetics

Background:

  • MicroRNA-410-3p (miR-410-3p) has a dual role in cancer, but its function in breast cancer is unclear.
  • Understanding miR-410-3p's role is crucial for developing novel breast cancer therapies.

Purpose of the Study:

  • To investigate the expression and function of miR-410-3p in breast cancer.
  • To elucidate the molecular mechanisms underlying miR-410-3p's action in breast cancer.

Main Methods:

  • Quantitative reverse transcription polymerase chain reaction (RT-qPCR) for expression analysis.
  • Analysis of The Cancer Genome Atlas (TCGA) expression data.
  • Cell proliferation assays (MTT, colony formation, EdU) and epithelial-mesenchymal transition (EMT) assessment.
  • Luciferase reporter assay to identify miR-410-3p targets.

Main Results:

  • miR-410-3p expression was significantly downregulated in breast cancer tissues compared to normal tissues.
  • Overexpression of miR-410-3p suppressed proliferation and EMT in MDA-MB-231 cells.
  • Inhibition of miR-410-3p enhanced proliferation in MCF7 cells.
  • Snail was identified as a direct target of miR-410-3p, and its overexpression rescued miR-410-3p's effects.

Conclusions:

  • miR-410-3p functions as a tumor suppressor in breast cancer.
  • The miR-410-3p/Snail axis plays a critical role in regulating breast cancer cell growth and EMT.
  • These findings provide a basis for targeting miR-410-3p in breast cancer treatment.